Fig. 2.

NLRP3 inflammasome inhibitor Ac-YVAD-CMK attenuates LPS-induced long-term depressive-like behaviors and memory deficit. (A, B) Results of the 24-point neurologic scoring system and rotarod test did not differ significantly among the control, YVAD, LPS, and YVAD + LPS groups at any time point (n = 10 mice/group, p>0.05). (C) In the novel object recognition test, mice in the LPS group had a significantly lower discrimination index than did animals in the control and YVAD groups, but in YVAD + LPS mice, the discrimination index was increased to the level of control (n = 10 mice/group, ^**p < 0.01 vs. control and YVAD groups, ^##p < 0.01 vs. LPS group). (D) Mice in the LPS group had significantly less sucrose preference than did animals in the control and YVAD groups, but mice in the YVAD + LPS group had significantly greater sucrose preference than did animals in the LPS group (n = 10 mice/group, ^**p < 0.01 vs. control and YVAD groups, ^##p < 0.01 vs. LPS group). (E–F) Mice in the LPS group had significantly longer immobility times than did animals in the control and YVAD groups in the tail suspension test (E) and forced swim test (F). However, in both tests, mice in the YVAD + LPS group had significantly shorter immobility time than did animals in the LPS group (n = 10 mice/group, ^**p < 0.01 vs. control and YVAD groups, ^##p < 0.01 vs. LPS group).